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Abstract. Since trace organic compounds such as pharmaceuticals in surface water have been a relevant
threat to drinking water supplies, in this study removal of pharmaceuticals and transformation of pharmaceuti-
cals into metabolites were investigated in the main source of micropollutants such as WWTPs and engineered
constructed wetlands. Pharmaceuticals were effectively removed by different WWTP processes and wetlands.
Pharmaceutical metabolites with relatively low log D value were resulted in the low removal efficiencies com-
pared to parent compounds with relatively high log D value, indicating the stability of metabolites. And the
constructed wetlands fed with wastewater eﬄuent were encouraged to prevent direct release of micropollu-
tants into surface waters. Among various pharmaceuticals, different transformation pattern of ibuprofen was
observed with significant formation of 1-hydroxy-ibuprofen during biological treatment in WWTP, indicat-
ing preferential biotransformation of ibuprofen. Lastly, transformation of pharmaceuticals depending on their
structural position was investigated in terms of electron density, and, the electron rich C1 =C2 bond of carba-
mazepine was revealed as an initial transformation position.
1 Introduction
For several decades, pharmaceuticals and personal care prod-
ucts (PPCPs) have been noticed as emerging problematic
compounds (Ternes et al., 1998; Snyder et al., 2003). In order
to reduce residual concentrations of PPCPs, various advance
treatments have been studied by many research groups (Lee
and Gunten, 2010; Rosal et al., 2010 and many others). How-
ever, high levels of PPCPs are still detected in wastewater ef-
fluent, surface waters, and drinking waters (Kim et al., 2007;
Lee et al., 2012; Yoon et al., 2010; Benotti et al., 2009). Since
those trace organic compounds have been detected even in
treated drinking waters by Benotti et al. (2009), control of
micropollutants has been important especially in the wastew-
ater treatment plant, the main source of the micropollutants
in the aquatic environments.
Meanwhile, constructed wetlands have been introduced as
an alternative to wastewater treatment for micropollutants re-
moval (Matamoros and Bayona, 2006). And few reports have
been focused on the relationship between log D and removal
of PPCPs in wetland systems. In previous study (Lee et al.,
2011), removal efficiency in constructed wetlands has been
investigated using corresponding octanol-water partitioning
coefficient of pharmaceuticals.
And few studies have been reported with regarding to be-
haviors of pharmaceutical metabolites in various environ-
ments (Stumpf et al., 1998; Quintana et al., 2005). The
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potential ecotoxicological effect of pharmaceutical metabo-
lites is still not known, thus, there is necessity to study fur-
ther about the fate of pharmaceutical metabolites in various
wastewater treatment processes.
In this study, removal and transformation of pharmaceuti-
cals has been investigated with regarding to physicochem-
ical and structural properties of pharmaceuticals and their
metabolites in various environments such as WWTPs and
constructed wetlands receiving wastewater eﬄuent.
2 Materials and methods
2.1 Target compounds
Various micropollutant compounds, including 9 pharma-
ceuticals, 11 selected metabolites, and 1 personal care
product, were selected in this study. Acetaminophen
(ACT), atenolol (ATN), carbamazepine (CBZ), diclofenac
(DCF), glimepiride (GMP), ibuprofen (IBU), naproxen
(NPX), O-desmethyl-naproxen (O-desmethyl-NPX),
sulfamethoxazole (SMX), and tri(2-chloroethyl) phos-
phate (TCEP) were obtained from Sigma-Aldrich (St.
Louis, MO). Caffeine (CAF) was purchased via Fluka
Chemie GmbH (Buchs, Switzerland). 1-hydroxy ibuprofen
(IBU-1OH), 2-hydroxy ibuprofen (IBU-2OH), ibupro-
fen carboxylic acid (IBU-CA), iopromide (IOP), and
N-acetyl-sulfamethoxazole (N-acetyl-SMX), paraxan-
thine, paraxanthine-1-methyl-d3, 4-hydroxy diclofenac
were purchased via Tronto Research Inc (Tronto, Canada).
Authentic carbamazepine metabolites 10, 11-dihydro-10, 11-
epoxycarbamazepine (CBZ-EP), 2-hydroxycarbamazepine
(CBZ-2OH), 3-hydroxycarbamazepine (CBZ-3OH), and 10,
11-dihydro-10-hydroxycarbamazepine (CBZ-10OH) were
provided from Norvatis Pharma AG (Basel, Switzerland).
Carbamazepine-d10 and 13C1-naproxen-d3 were purchased
from Cambridge Isotope Laboratories (Andover, MA,
US). Atenolol-d7 and diclofenac-d4 were obtained from
C/D/N Isotopes (Pointe-Claire, Canada). Ibuprofen-d3, N4-
acetylsulfamethoxazole-d4, and sulfamethoxazole-d4 were
obtained from Tronto Research Inc (Tronto, Canada). HPLC
grade methanol was obtained from J.T. Baker (Philipsburg,
NJ, US). Methyl tert-butyl ether (MTBE) and formic acid
were obtained from Sigma-Aldrich (St. Louis, MO, US).
Information of target compounds and their metabolites is
listed in Table 1. The log Kow, log Dow, and pKa for inves-
tigated compounds was calculated based on the molecular
structures using ChemAxon Marvin Calculator Plugin. The
log Dow is a pH dependent log Kow value and in this study
log D at pH 7 was used.
2.2 Sample collection
In June 2010, water samples were collected from each
process (influent and eﬄuents of the various unit opera-
tions) in three different wastewater treatment plant. One
is Gwangju primary municipal wastewater treatment plant,
which is operated with the nitrogen and phosphorus removal
treatment system (600 000 m3 day−1). Second sampling sites
was Gwangju secondary municipal wastewater treatment
plant, which had two different treatment trains (Conventional
Activated Sludge and Modified Ludzack-Ettinger (MLE)
process), having total capacity up to 120 000 m3 day−1. In
those two different Gwangju municipal WWTPs, sodium
hypochlorite was added as a disinfectant and final eﬄuent
samples were collected after disinfection process. Addition-
ally, water samples from both Damyang wastewater treat-
ment plant and Damyang constructed wetlands were col-
lected and studied. There was no disinfection system in
Damyang WWTP and final eﬄuent was collected after sec-
ondary treatment. Damyang constructed wetlands connected
to Damyang wastewater treatment plant is free surface flow
constructed wetlands, which have two different ponds, con-
taining Aporus ponds followed by Typha ponds. The hy-
draulic retention time of wetlands is approximately 6 h and
flow rate is 1800 m3 day−1. Every sample was spiked with a
biocide sodium azide and ascorbic acids to quench any resid-
ual oxidant in the field.
2.3 SPE and LC-MS/MS analysis
After filtration using glass fiber membrane filter, all analytes
were extracted by using AutoTrace automated solid phase
extraction (SPE) system (Caliper Corporation, Hopkington,
MA), as depicted by Vanderford and Snyder (2006). Briefly,
the 6 mL, 500 mg hydrophilic-lipophilic balance (HLB) glass
cartridges (Waters Corporation, Milford, MA) were precon-
ditioned in the following order: 5 mL of MTBE, 5 mL of
methanol, and 5 mL of deionized water. 500 mL of samples,
spiked with the addition of standards for internal calibration,
were loaded onto the cartridges at 15 mL min−1 in duplicate,
after which the cartridges were rinsed with 5 mL of deionized
pure water, and then dried with a steam of air for 50 min. The
cartridges were eluted with 5 mL of methanol, followed by
5 mL of 1/9 (v/v) methanol/MTBE. The eluted solution was
concentrated in a water bath at 40 ◦C with a gentle stream
of air to a final volume of 500 µL, which was a concentra-
tion factor of 1000. The levels of pharmaceuticals and their
metabolites were then measured using a Water 2695 Sepa-
rations Module (Waters, Milford, MA) coupled with a Mi-
cromass Quattro Micro triple quadrupole tandem mass spec-
trometer (Micromass, Manchester, UK) in electrospray ion-
ization mode (ESI). A 20 µL sample loop and 150× 2.1 mm
SunFire C18 column with a particle size of 3.5 µm (Waters,
Milford, MA) was employed for analyte separation. A bi-
nary gradient, consisting of 0.1 % formic acid (eluent A)
and 100 % acetonitrile (eluent B), was used at a flow rate
of 0.2 mL min−1. Selected PPCPs and their metabolites was
analyzed using two different gradients. The gradient used for
the PPCPs and most of the metabolites was: gradient with
15 % of B was held for 4 min, increased linearly to 80 % for
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Table 1. Tested parent compounds and metabolites.
 
Table 1. Tested parent compounds and metabolites. 
Analytes  Uses  Structure  pKa
a
  log Kow
a
 
log D
a
 
at pH7  
Acetaminophen  Analgesic  
 
9.46  0.91 0.91  
Glimepiride  Anticholesterol  
 
4.32  3.12 2.18  
tri(2-chloroethyl) phosphate 
(TCEP) 
Flame retardant  
 
N.E  2.11 2.11  
Carbamazepine (CBZ) Anticonvulsant  
 
N.E  2.77 2.77  
CBZ-EP 
Carbamazepine 
metabolite 
 
N.E. 1.97 1.97 
CBZ-2OH 
Carbamazepine 
metabolite 
 
9.3 2.66 2.66 
CBZ-3OH 
Carbamazepine 
metabolite 
 
9.46 2.66 2.66 
CBZ-10OH 
Carbamazepine 
metabolite 
 
14.1 1.73 1.73 
Sulfamethoxazole  Antibiotic  
 
6.16  0.79 0.14  
N
4
-acetylsulfamethoxazole 
Sulfamethoxazole 
metabolite 
 
5.88 0.86 0.1 
Diclofenac  Analgesic  
 
4.00  4.26 0.96  
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Table 1. Continued.
4-hydroxyl-diclofenac 
Diclofenac 
metabolite 
 
3.76, 
8.61 
3.96 0.89 
Naproxen  Analgesic  
 
4.19  2.99 0.25  
O-desmethyl-naproxen 
Naproxen  
metabolite 
 
4.34, 
9.78  
3.9  0.23  
Ibuprofen  Analgesic  
 
4.85  3.84 1.71  
1-hydroxyl-ibuprofen 
Ibuprofen 
metabolite 
 
4.90 2.85 0.77 
2-hydroxyl-ibuprofen 
Ibuprofen 
metabolite 
 
4.63 2.08 0.03 
Ibuprofen carboxylic acid 
Ibuprofen 
metabolite 
 
3.97, 
4.77 
2.78 -2.36 
Caffeine  Stimulant  
 
N.E  -0.55 -0.55  
Paraxanthine 
Caffeine 
metabolite 
 
10.76 0.24 0.24 
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a log P, log D, and pKa value were calculated from the Software Calculator Plugins.
b N.E: nonexistent at pH range 1–14.
6 min, held for 3 min with 80 % of B and then linearly in-
creased to 100 % for 7 min. The gradient used for the carba-
mazepine metabolites was: gradient with 10 % of B increased
linearly to 40 % for 15 min, increased linearly to 90 % for
10 min, and held until 30 min (Kang et al., 2008). A 5 min
equilibration step with gradient of 10 % B was used at the
beginning of each run. Detail LC-MS/MS analysis condition
and analytical parameters of target compounds are shown in
Table 2.
2.4 Molecular orbital calculations
Molecular orbital were calculated single determinant
(Hartree-Fock) for optimization bearing the minimum energy
obtained at the AM1 level. All semi-empirical calculations to
obtain the point charge and electron density for pharmaceu-
ticals and metabolites were performed in MO-G with a SCI-
GRESS package version 7.7 (Fujitsu Co. Ltd.) (Watanabe et
al., 2003).
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Table 2. Analytical parameters of selected compounds (MDL: method detection limit; RL: reporting limit).
Compound Retention Cone Collision Parent Daughter MDL RL
time (min) voltage (V) energy (eV) ion (m/z) ion (m/z) (ng L−1) (ng L−1)
ESI negative
Diclofenac 15.53 15 10 294 249 1.3 3.9
Diclofenac-d4 11.23 15 12 298 254
4-OH-DCF 13.70 20 12 310 266 5.1 15.3
Ibuprofen 15.70 15 8 205 161 1.2 3.6
Ibuprofen-d3 11.63 15 8 208 164
IBU-1OH 12.87 15 7 221 177 5.8 17.5
IBU-2OH 12.23 17 7 221 177 0.9 2.7
IBU-CA 12.27 12 5 235 191 2.3 6.8
Naproxen 9.84 10 8 229 185 3.3 10.0
Naproxen-d3 9.83 10 6 233 189
O-desmethyl-NPX 8.10 15 12 215 171 1.2 3.5
N-acetyl-SMZ 7.71 30 13 294 198 0.9 2.7
TCEP 9.12 30 16 285 161 7.9 23.8
ESI positive
Acetaminophen 3.98 28 17 152 110 0.5 1.5
Acetaminophen-d4 3.98 28 17 156 114
Glimepiride 11.34 28 13 491 352 1.5 4.6
Sulfamethoxazole 7.83 30 18 254 156 0.6 1.7
Sulfamethoxazole-d4 7.80 25 15 258 160
Caffeine 6.11 35 20 195 138 1.5 4.6
Paraxanthine 2.72 30 22 181 124 9.3 27.9
Paraxanthine-d3 2.72 30 22 184 124
Carbamazepine 19.31 35 18 237 194 0.7 2.1
Carbamazepine-d10 8.74 35 18 247 204
CBZ-EP 15.64 28 24 253 180 1.2 3.6
CBZ-2OH 14.34 35 20 253 210 13.0 3.9
CBZ-3OH 15.78 35 20 253 210 1.5 4.5
CBZ-10OH 13.63 30 20 255 194 0.2 0.5
Table 3. Concentrations of selected PPCPs in WWTPs and wetlands.
PPCPs Gwangju Primary Gwangju Secondary Damyang WWTP and Constructed wetlands
WWTP WWTP
WWTP WWTP WWTP WWTP WWTP WWTP Acorus Typha Wetland
influent eﬄuent influent eﬄuent influent eﬄuent wetland wetland eﬄuent
(ng L−1) (ng L−1) (ng L−1) (ng L−1) (ng L−1) (ng L−1) (ng L−1) (ng L−1) (ng L−1)
Caffeine 72 471.2 < 4.6 45 457.0 1857.8 36 880.6 < 4.6 < 4.6 47.0 < 4.6
Carbamazepine 2085.4 108.3 1668.8 362.8 844.5 417.2 387.1 161.4 268.3
Sulfamethoxazole 6048.6 88.8 8092.9 70.7 409.7 27.4 17.9 7.4 17.4
Acetaminophen 162 159.9 1705.8 227 705.4 180.5 194 586.8 189.7 354.8 549.5 349.6
Ibuprofen 2626.0 < 3.6 4576.5 166.6 1645.3 17.9 43.2 52.9 47.2
Naproxen 1140.5 < 10.0 1778.5 10.7 203.5 < 10.0 11.4 < 10.0 < 10.0
Diclofenac 2673.5 111.7 2702.8 < 3.8 150.5 19.8 20.15 < 3.8 8.9
Glimepiride 18 895.3 197.4 40 338.6 86.6 36.8 12.3 11.3 < 4.6 14.4
TCEP 6011.8 320.3 4774.7 < 23.8 2608 340.6 277.85 186.35 268.4
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Table 4. Concentrations of parent pharmaceuticals and their metabolites in WWTPs and wetlands.
Parent compounds and Gwangju Primary Gwangju Secondary Damyang WWTP and Constructed wetlands
their metabolites WWTP WWTP
WWTP WWTP WWTP WWTP WWTP WWTP Acorus Typha Wetland
influent eﬄuent influent eﬄuent influent eﬄuent wetland wetland eﬄuent
(ng L−1) (ng L−1) (ng L−1) (ng L−1) (ng L−1) (ng L−1) (ng L−1) (ng L−1) (ng L−1)
Caffeine 72 471.2 < 4.6 45 457.0 < 4.6 36 880.6 < 4.6 < 4.6 47.0 < 4.6
Paraxanthine 8215.3 33.9 10 442.1 < 27.9 3222.3 < 27.9 < 27.9 < 27.9 < 27.9
Sulfamethoxazole 6048.6 88.8 8092.9 166.6 409.7 27.4 17.9 7.4 17.4
N-acetyl-SMZ 5224.8 64.5 6224.2 72.4 152.6 4.9 < 2.7 < 2.7 5.3
Naproxen 1140.5 < 10.0 1778.5 10.7 203.5 < 10.0 11.4 < 10.0 < 10.0
O-desmethyl-NPX 191.5 31.7 125.0 31.1 245.0 9.3 < 3.5 < 3.5 7.75
Diclofenac 2673.5 111.7 2702.8 86.6 150.5 19.8 20.15 < 3.8 8.9
4-OH-DCF 530.6 582.1 396.0 504.6 212.0 40.2 21.15 < 15.3 < 15.3
3 Results and discussion
3.1 Removal of pharmaceuticals and personal care
products in WWTPs and wetlands
Removal of PPCPs in municipal wastewater treatment plants
and constructed wetlands were investigated and summarized
by comparing the concentrations of PPCPs in the influent
and final eﬄuent of each WWTP in Table 3. Unfortunately,
the contribution of different transport mechanisms such as
biodegradation, adsorption to sludge and sediments, and oxi-
dation during disinfection was not considered here. Gwangju
WWTP was found as a major source, releasing tons of mi-
cropollutants to the Yeongsan River water, and, the concen-
trations of PPCPs in Gwangju WWTPs (∼ µgL−1) were gen-
erally much higher than in Damyang WWTP (∼ ng L−1), pre-
sumably resulting from the dense populations in Gwangju
area.
Particularly, high concentrations of caffeine and ac-
etaminophen in WWTP influents reflect frequent use and
ingestion of those compounds in this urban area. Most
of PPCPs exhibited high removal efficiency (> 90 %) dur-
ing the WWTPs processes, except for carbamazepine re-
moval in Gwangju secondary WWTP (removal efficiency
at 74 %). After discharge of WWTP eﬄuent into connected
constructed wetlands, levels of some PPCPs (carbamazepine,
sulfamethoxaolze, diclofenac, and TCEP) slightly decreased.
This result indicates that operation of wastewater stabiliza-
tion ponds or wetlands would be helpful to prevent release of
micropollutants into surface water. Our research group has
previously been studied the Damyang constructed wetlands
with respect to the control of organic micropollutants, and,
reported the efficiency of wetland treatments depending on
the wetland characteristics and properties of micropollutants
(Park et al., 2009). Many other studies have also been sup-
ported the necessity of additional wetland treatments for mi-
cropollutants control (Matamoros and Bayona, 2006; Conkle
et al., 2008).
3.2 Transformation of pharmaceuticals and formation of
metabolites in WWTPs
Table 4 shows occurrence of parent pharmaceuticals and
their metabolites in WWTPs and wetlands system. In the
WWTPs influent, most metabolites were detected at high
level of concentrations with range of 100∼ 10 000 ng L−1
compared to WWTP eﬄuents, indicating dominant transfor-
mation pathway of metabolite resulting from human body
rather than microbial transformation. However, after pass-
ing the WWTPs, concentrations of most metabolites were
observed higher than that of parent compounds, indicating
the structural stability of the metabolites during the WWTP
process relative to their parent compounds. The stability of
metabolites may be related to the difference of the log D
value between parent pharmaceutical compounds and phar-
maceutical metabolites. As pharmaceuticals transformed into
their metabolites, their log D value at pH 7 slightly de-
creased (Table 1). Considering the dominant removal mecha-
nism of micropollutants in WWTP process (i.e., sorption and
biodegradation), decrease of log D may result in the reduc-
tion of sorption of pharmaceutical metabolites on the sludge
surface. Consequently, pharmaceutical metabolites would be
detected at higher levels than parent compounds in WWTP
eﬄuents.
In case of sulfamethoxazole metabolite, even though
the concentrations of N-acetyl-sulfamethoxazole were low
enough in wastewater eﬄuents, by considering retrans-
formation of acetylated metabolite back into its par-
ent compound, N-acetyl-sulfamethoxazole should be as-
sumed as a pharmaceutically active parent compound (Gö-
bel et al., 2005). And based on this reason, monitoring
of N-acetyl-sulfamethoxazole is important and necessary
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Figure 1. Transformation of ibuprofen in different WWTPs sys-
tem: (a) Gwangju primary WWTP, (b) Gwangju secondary WWTP,
(c) Damyang WWTP and constructed wetlands.
for the effective control of micropollutants in aquatic
environment.
During the engineered constructed wetland treatments,
there was no specific change of pharmaceutical metabo-
lites in exception with ibuprofen metabolites. As can be
seen in Fig. 1, ibuprofen was differently transformed de-
pending on the treatment process. In WWTPs influent,
2-hydroxyibuprofen, the well-known human metabolite of
ibuprofen was dominant, whereas, after the activated sludge
treatment, concentrations of 1-hydroxyibuprofen indicate the
highest level in all WWTPs and wetlands. Significant for-
mation of 1-hydroxyibuprofen in WWTPs might be possi-
bly explained by preferential microbial metabolism in ac-
Figure 2. Distribution of carbamazepine metabolites in different
WWTPs system: (a) Gwangju primary WWTP, (b) Gwangju sec-
ondary WWTP, (c) Damyang WWTP and constructed wetlands.
tivated sludge treatment process. In the additional experi-
mental results conducted in river waters, completely differ-
ent composition of ibuprofen metabolites was observed. 2-
hydroxy-ibuprofen was found to be dominant in both river
waters, Yeongsan River and Seomjin River (data are not
shown). This might infer that 2-hydroxyibuprofen is much
more persistent and stable than 1-hydroxyibuprofen and even
than parent compound, ibuprofen, as previously mentioned
by Weigel et al. (2004).
In contrast, carbamazepine did not exhibit any change in
transformation behavior during WWTPs and wetland treat-
ments (Fig. 2). All the selected carbamazepine metabolites,
10,11-epoxy-carbamazepine, 2-hydroxycarbamazepine,
www.drink-water-eng-sci.net/6/89/2013/ Drink. Water Eng. Sci., 6, 89–98, 2013
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Table 5. Calculations of frontier electron density for carbamazepine.
Atom HOMO Nucleophilic Frontier Electrophilic Frontier Radical Frontier LUMO
List Density Density Density Density Density
C1 0.148 0.202 0.215 0.208 0.131
C2 0.119 0.252 0.175 0.214 0.169
C3 0.064 0.222 0.108 0.165 0.136
C4 0.118 0.113 0.184 0.148 0.057
C5 0.046 0.201 0.088 0.145 0.090
C6 0.067 0.113 0.136 0.124 0.049
N7 0.074 0.003 0.211 0.107 0.000
C8 0.039 0.141 0.080 0.111 0.054
C9 0.010 0.117 0.036 0.076 0.030
C10 0.068 0.214 0.111 0.163 0.133
C11 0.012 0.088 0.044 0.066 0.013
C12 0.046 0.094 0.117 0.105 0.047
C13 0.024 0.048 0.076 0.062 0.007
C14 0.111 0.129 0.173 0.151 0.072
C15 0.016 0.043 0.078 0.060 0.010
C16 0.012 0.010 0.021 0.016 0.000
N17 0.007 0.002 0.072 0.037 0.000
O18 0.018 0.002 0.064 0.033 0.000
H19 0.000 0.001 0.001 0.001 0.000
H20 0.000 0.000 0.001 0.001 0.000
H21 0.001 0.002 0.002 0.002 0.001
H22 0.002 0.001 0.003 0.002 0.000
Figure 3. Structure of carbamazepine.
3-hydroxycarbamazepine and 10-hydroxycarbamazepine
was detected in influents, eﬄuents of WWTPs and wetlands.
Even though the levels of 10,11-epoxy-carbamazepine
was low, the eco-toxicological effect of CBZ-EP on the
environment is worthy of further examination due to its
pharmaceutically active property like its parent compound,
carbamazepine. The most dominant carbamazepine metabo-
lite was 10-hydroxy-carbamazepine. The predominant
formation of CBZ-10OH might be due to the different
distribution of electron density of atoms in carbamazepine.
3.3 Effect of electron density on transformation of
carbamazepine into metabolites
In previous studies, electron density distribution of chemicals
has been used to find the initial positions of OH radical attack
in oxidation (Watanabe et al., 2003; Jung et al., 2010; Heim-
stad et al., 2009). A higher electron density indicates more
electrons in the bonds, resulting in electrophilic reaction
(Horikoshi et al., 2004; Kaneco et al., 2006). In this study,
electron density of pharmaceutical was examined to find
the initial transformation position in various transformation
mechanisms including biological process and photochemical
oxidations. In previous study, Park et al. (2009) suggested
that hydrolysis reaction at the amide and urea functional
groups may lead to the biological transformation of carba-
mazepine. Frontier electron density of carbamazepine cal-
culated by MOPAC, Scigress software is shown in Table 5.
Radical frontier density, the averaged value of nucleophilic
frontier density and electrophilic frontier density, are used in
this study. Based on the electron density of carbamazepine,
the carbon bonds between C1 and C2 showed the largest fron-
tier electron density (0.208 and 0.214, respectively). This
electron rich carbon bond of the olefin structure may pro-
vide the initial position of oxidation. Prevalent occurrence of
specific carbamazepine metabolites such as CBZ-EP, CBZ-
10OH, and CBZ-DiOH in environment are presumably re-
lated with this oxidation pathway. However, other metabo-
lites were difficult to find a relationship between transforma-
tion and electron density. The reason for this low relationship
is thought that there might be some other different preferred
transformation pathways depending on the intrinsic property
of chemicals rather than electron density derived transforma-
tion. However, electron density of chemicals is still believed
as a key parameter to elucidate unknown pathway in various
processes, especially in oxidation process.
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4 Conclusions
Removal and transformation of pharmaceuticals in WWTPs
and constructed wetlands were extensively investigated in
this study. Pharmaceuticals were effectively removed by dif-
ferent WWTP processes and wetlands. From this study,
the additional operation of wastewater management wet-
lands was encouraged to prevent direct discharge of mi-
cropollutants into surface waters. And additionally, phar-
maceutical metabolites were found to be more stable than
the parent compounds during WWTP processes due to
the lower log D value of metabolites than parent com-
pounds. Different transformation pattern of pharmaceuticals
was also observed, especially in transformation of ibupro-
fen. 1-hydroxyibuprofen was dominantly formed during bio-
logical treatment in WWTP, indicating preferential biotrans-
formation of ibuprofen. At last, electron density of carba-
mazepine was examined to elucidate the transformation path-
way. The electron rich C1 =C2 bond in olefin structure of
carbamazepine was revealed as an initial transformation po-
sition.
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